A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Recruiting

Phase 1

Phase 2

ATG & AdalimumabA Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Sponsor:

City of Hope Medical Center

Code:

NCT07061574

Conditions

Type 1 Diabetes

New Onset

Eligibility Criteria

Sex: All

Age: 9 - 21

Healthy Volunteers: Not accepted

Interventions

Anti-thymocyte globulin (ATG)

verapamil extended-release capsule

Adalimumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-11. This information was provided to ClinicalTrials.gov by City of Hope Medical Center on 2026-03-16.